CSF-1R Expression in Tumor-Associated Macrophages Is Associated With Worse Prognosis in Classical Hodgkin Lymphoma

Young Wha Koh; Chansik Park; Dok Hyun Yoon; Cheolwon Suh; Jooryung Huh
April 2014
American Journal of Clinical Pathology;Apr2014, Vol. 141 Issue 4, p573
Academic Journal
Objectives: The aim of this study was to determine the prognostic relevance of colony-stimulating 1 receptor (CSF-1R) expression in both Hodgkin/Reed-Sternberg (HRS) cells and the surrounding cells (non-HRS cells) in patients with classical Hodgkin lymphoma (CHL) . Methods: Diagnostic tissues from 112 patients with CHL treated with doxorubicin, bleomycin, vinblastine, and dacarbazine were evaluated retrospectively by immunohistochemical analysis for CSF-1R and CD68 and CD163 for tissue-associated macrophages. Results: High numbers (≥30%) of non-HRS cells expressing CSF-1R conferred inferior event-free survival and overall survival in univariate and multivariate analysis. High numbers of non-HRS cells expressing CSF-1R were significantly associated with a high number of tumor-associated macrophages as detected by CD163 expression (P < .001). In particular, coexpression of CSF-1R and CD163 was associated with a worse survival outcome than either CSF-1R or CD163 expression alone or no expression. Conclusions: Our data demonstrate that a high number of non-HRS cells expressing CSF-1R are correlated with an increased tumor macrophage content and worse survival.


Related Articles

  • Factors affecting intrapatient liver and mediastinal blood pool F-FDG standardized uptake value changes during ABVD chemotherapy in Hodgkin's lymphoma. Chiaravalloti, Agostino; Danieli, Roberta; Abbatiello, Paolo; Pietro, Barbara; Travascio, Laura; Cantonetti, Maria; Guazzaroni, Manlio; Orlacchio, Antonio; Simonetti, Giovanni; Schillaci, Orazio // European Journal of Nuclear Medicine & Molecular Imaging;Jun2014, Vol. 41 Issue 6, p1123 

    Purpose: The aim of our study was to assess the intrapatient variability of 2-deoxy-2-(F)-fluoro- D-glucose (F-FDG) uptake in the liver and in the mediastinum among patients with Hodgkin's lymphoma (HL) treated with doxorubicin (Adriamycin), bleomycin, vinblastine and dacarbazine (ABVD)...

  • CITATIONS AND CLINICIANS' NOTES: HODGKIN'S LYMPHOMA.  // Current Medical Literature: Leukemia & Lymphoma;2004, Vol. 12 Issue 4, p84 

    Presents citations and clinicians' notes on Hodgkin's lymphoma. Retrospective analysis on the chlorambucil, vinblastine, procarbazine, doxorubicicn, bleomycin, vincristine and etoposide regimen; Relation of the severe pulmonary toxicity in patients with advanced-stage Hodgkin's disease treated...

  • ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trials. Fox, Christopher // Current Medical Literature: Leukemia & Lymphoma;2013, Vol. 21 Issue 3, p82 

    The article discusses research on the safety and efficacy of doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) in older patients with classical Hodgkin lymphoma (cHL) who were treated within HD10 and HD11 trials. It references a study by B. Böll et al, published in a 2013 issue of...

  • Patterns of disease progression and outcomes in a randomized trial testing ABVD alone for patients with limited-stage Hodgkin lymphoma. D. A. Macdonald; K. Ding; M. K. Gospodarowicz; W. A. Wells; R. G. Pearcey; J. M. Connors; J. N. Winter; S. J. Horning; M. S. Djurfeldt; L. E. Shepherd; R. M. Meyer // Annals of Oncology;Oct2007, Vol. 18 Issue 10, p1680 

    Background: In the National Cancer Institute of Canada Clinical Trials Group/Eastern Cooperative Oncology Group HD.6 trial, progression-free survival was better in patients randomized to therapy that included radiation, compared to doxorubicin (Adriamycin®), bleomycin, vinblastine and...

  • Cyclic Fever in Hodgkin's Disease (Pel—Ebstein Fever). Good, Gary R.; DiNubile, Mark J. // New England Journal of Medicine;2/16/95, Vol. 332 Issue 7, p436 

    The article discusses the medical case of a middle-aged man admitted after he reported fever, night sweats and nonproductive coughing. The patient took antipyretic medication during periods of fever. The patient's wife recorded his temperature a majority of the days he had been sick. Nodular...

  • Reduced Treatment Intensity in Patients with Early-Stage Hodgkin's Lymphoma. Engert, Andreas; Pl�tschow, Annette; Eich, Hans Theodor; Lohri, Andreas; D�rken, Bernd; Borchmann, Peter; Berger, Bernhard; Greil, Richard; Willborn, Kay C.; Wilhelm, Martin; Debus, J�rgen; Eble, Michael J.; S�kler, Martin; Ho, Antony; Rank, Andreas; Ganser, Arnold; Tr�mper, Lorenz; Bokemeyer, Carsten; Kirchner, Hartmut; Schubert, J�rg // New England Journal of Medicine;8/12/2010, Vol. 363 Issue 7, p640 

    Background: Whether it is possible to reduce the intensity of treatment in early (stage I or II) Hodgkin's lymphoma with a favorable prognosis remains unclear. We therefore conducted a multicenter, randomized trial comparing four treatment groups consisting of a combination chemotherapy regimen...

  • Research & Markets: Brentuximab Vedotin - First Treatment Option for Relapsed Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (Subset of Non-Hodgkin Lymphoma).  // Biomedical Market Newsletter;8/23/2011, Vol. 21, p77 

    The article discusses the need for drugs with enhanced toxicity and efficacy in treating Hodgkin and non-Hodgkin lymphoma. It says that the relapse rate for Hodgkin lymphoma and anaplastic large cell lymphoma (ALCL) patients are 30% and 50%. It mentions the report "Brentuximab Vedotin: First...

  • Neutropenia and Neutropenic Complications in ABVD Chemotherapy for Hodgkin Lymphoma. Vakkalanka, Bhanu; Link, Brian K. // Advances in Hematology;2011, Vol. 2011, p1 

    A combination of Adriamycin (a.k.a. Doxorubicin), Bleomycin, Vinblastine, and Dacarbazine (ABVD) is the most commonly used chemotherapy regime for Hodgkin lymphoma. This highly effective treatment is associated with a significant risk of neutropenia. Various strategies are adopted to counter...

  • Lack of association of tumor-associated macrophages with clinical outcome in patients with classical Hodgkin's lymphoma. Azambuja, D.; Natkunam, Y.; Biasoli, I.; Lossos, I. S.; Anderson, M. W.; Morais, J. C.; Spector, N. // Annals of Oncology;Mar2012, Vol. 23 Issue 3, p736 

    Background: A recent study demonstrated that an increased number of CD68+ macrophages were correlated with primary treatment failure, shortened progression-free survival (PFS) and disease-specific survival (DSS) in patients with classical Hodgkin's lymphoma (cHL). Patients and methods: The aim...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics